An autonomous pathogen detection and disinfection mobile platform having a small footprint, such that embodiments of the platform are deployable within interior spaces such as hospital, clinics, and other healthcare facilities. The platform includes a detection chamber that efficiently identifies a presence of a pathogen, such as a microorganism. The platform also includes a disinfection discharge component, such as a discharge needle, that treats a surface that includes a presence of a pathogen. As an autonomous mobile device, the platform includes sensors, cameras, or similar devices to detect surrounding surfaces, such that a computing device disposed on the platform plots a dynamic path for the platform based on received feedback.
A61L 2/24 - Appareils utilisant des opérations programmées ou automatiques
A61L 2/03 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques du courant électrique, p. ex. électrolyse
2.
METHOD OF TREATING LONG-COVID INDUCED NEUROLOGIC DISEASES
A method of treating or preventing Alzheimer's disease or related dementias in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Brain gene expression profiles of severe COVID-19 patients show increased expression of several innate immune response genes and genes implicated in Alzheimer's disease pathogenesis. The gene expression signature includes genes involved in inflammation, protein folding/trafficking, complement activation, calcium homeostasis, and amyloid/tau processing. The gene expression signature is correlated with tau pathology, α-synuclein, and demyelination with neuroinflammation being increased in old versus young CoV-2 infected mice.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
In accordance with some embodiments, various examples of systems, methods, and media for detecting falsified Wi-Fi signals. A system detects a group of nearby access points (APs) broadcasting Wi-Fi signals. A determination is made whether the group of nearby APs contains at least one falsified Wi-Fi signal. Whenever it is determined that the group of nearby APs does contains at least one falsified Wi-Fi signal, an analysis is performed of each AP of the group of nearby APs. The analysis uses at least one of: a pair-wise comparison of AP locations, or an analysis of physical layer attributes of the signals broadcasted by the APs. APs of the group of nearby APs are identified that are falsified. A mitigation action is initiated relative to the falsified APs that are identified.
Described herein relates to an apparatus and method for holding a solid state NMR rotor under vacuum gas exposure during ssMAS experiments. As such, in an embodiment, the novel gas loader cell apparatus may be miniaturized and/or formed from a material other than glass to provide ease of use, efficient use of gaseous materials, affordability, and portability. Additionally, in an embodiment, a novel forming tool may be used to form the cavity holding the rotor end cap.
An apparatus configured to increase photoluminescence, generated by a substantially monolayer 2D heterostructure having a heterojunction, by at least several orders of magnitude. A method for use of same in the regime when such heterojunction is placed between pieces of a plasmonic material with a sub-nanometer distance therebetween.
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
G02B 5/00 - Éléments optiques autres que les lentilles
H01L 33/50 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les éléments du boîtier des corps semi-conducteurs Éléments de conversion de la longueur d'onde
6.
THERAPEUTIC AGENT-LOADED TISSUES FOR CORNEAL TRANSPLANT
Disclosed herein are methods of loading therapeutic agents into corneal tissues, corneal tissues including therapeutic agents, and surgical methods including keratoplasties in which corneal tissues having one or more therapeutic agents loaded therein are transplanted into a patient.
An example system includes an anatomical model; a camera configured to image the anatomical model; an instrument; a controller operably coupled to the camera and the instrument, the controller comprising a processor and a memory, the memory having computer-executable instructions stored thereon that, when executed by the processor, cause the controller to: receive an image from the camera; determine, based on the image, a position of the instrument relative to the anatomic model; display a simulated image of an anatomical structure based on the position of the instrument relative to the anatomical model. An example method includes simulating a procedure by receiving an image from a camera; determining a position of an instrument relative to an anatomical model based on the image; and displaying a corresponding anatomical image from an imaging procedure based on the position of the instrument relative to the anatomical model.
Systems, methods, and apparatus for frequency domain diffuse correlation spectroscopy are provided. In some embodiments, the system comprises: an intensity modulated coherent light source; a photon counting detector; at least one hardware processor that is programmed to: cause the light source to emit light at a plurality of different intensity modulation frequencies toward a tissue sample; detect, for each of the plurality of different modulation frequencies, photon counts over a predetermined period of time; determine, for each of the plurality of modulation frequencies, a normalized intensity auto-correlation function; estimate a plurality of properties of the tissue sample using the plurality of intensity auto-correlation functions; and output at least one of the plurality of properties.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
Compositions, systems and methods of removing ammonia from fish storage systems are presented. A chemical water conditioner comprised of sodium formaldehyde bisulfite, cornstarch, dye and alcohol was found to have a high ammonia removal efficiency in seawater. A combination of this chemical water conditioner with modified chabazite and phosphate buffer exhibited high ammonia removal efficiency in both seawater and freshwater.
Norwegian University of Life Sciences (NMBU) (Norvège)
Inventeur(s)
Baker, Bill J.
Calcul, Laurent J.
Pham, Kim
Kokkaliari, Sofia
Crawford, Alexander Dettmar
Shahbazi, Nargess
Abrégé
Pharmaceutical compositions containing one of five novel alkaloids isolated from a deep water Antarctic tunicate and methods of uses thereof are presented. The alkaloids belong to a family of compounds with known central nervous system (CNS) activity. The compounds display more oxidation than other members of the family, which may bestow additional bioactivity.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present disclosure provides for a method of treating Friedrich's Ataxia in a subject in need thereof comprising administering to the subject a composition to upregulate type 2 ryanodine receptors (Ryr2), a composition to activate Ca2+ release, a composition to upregulate SERCA2a, a composition to upregulate Phasoplamban (PLN), a composition to upregulate Ca2+/calmodulin-dependent protein kinase II (CaMKII), or any combination thereof. Further provided herein is a method of diagnosing Friedrich's Ataxia and a kit related thereto.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/055 - Phénols le noyau aromatique étant substitué par un halogène
A61K 31/566 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol ayant un groupe oxo en position 17, p. ex. œstrone
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
12.
Integrity and Privacy-Preserving Federated Learning in a Smart Factory Using Smart Contracts and Merkle Tree-Based Key Management
An example system and method that can provide integrity and privacy-preserving communication and integrated operation in smart factory and other IOT applications using smart contracts in blockchain and Merkle Tree-based key management operations. The exemplary Merkle tree-based key management can ensure all communication, control operations, and shared models (e.g., Federated Learning models) are encrypted prior to transmission and sharing with other nodes in the network, with keys being split into parts to each of multiple recipients and later assembled to allow blocking consensus/validation to be performed.
H04L 9/00 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité
H04L 9/06 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité l'appareil de chiffrement utilisant des registres à décalage ou des mémoires pour le codage par blocs, p. ex. système DES
13.
MULTIFUNCTIONAL PRINTER FOR DIRECT PRINTING METALS ON FABRICS
The present invention relates to a multifunctional printer system designed for printing electronic circuits directly onto fabrics, ideal for creating wearable electronics. This system integrates a laser burner, a dual-tube Hydrogen Evolution Assisted (HEA) electroplating nozzle, and a passivation nozzle into a single printer head. The laser burner creates conductive templates on the fabric by burning specific patterns, which are then metalized using the HEA electroplating nozzle to apply copper. This process is enhanced by hydrogen evolution, which improves the quality of copper deposition. Following metalization, an insulating material is applied over the copper patterns using the passivation nozzle to protect and insulate the electronic circuits. The system includes a control unit equipped with a digital microscope and image processing capabilities, enabling real-time monitoring and dynamic adjustment of printing parameters. This approach allows for efficient, precise, and scalable production of integrated electronic textiles.
Provided is a solid precipitation reactor useful for waste-water treatment. The reactor can include a reaction chamber configured to receive feedwater and to allow particulates to at least partially precipitate from the feedwater to form an effluent, and a membrane module having at least one membrane filter configured to receive effluent from the reaction chamber and to filter suspended particulates from the effluent to produce a permeate and a concentrate. The concentrate can be reintroduced to the re-action chamber to allow additional particulates to precipitate. Systems and methods for wastewater treatment, and methods for regenerating a zeolite cation exchanger, using the solid precipitation reactor are also provided.
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
A SyntheticMulti-Exposure Speckle Imaging (syMESI) methodology necessarily utilizing an optical interferometer apparatus as part of the speckle imaging system to overcome the optical detector noise that conventionally limits the reliable and accurate determination of a speckle contrast characteristic at low exposure times. The use of such methodology enabled a quantitative determination of absolute value(s) of changes of motion at the target object (such as blood flow changes in tissue) at low photon budget of less than 40 counts of average detection intensity and/or quantitative imaging of the blood flow at the object in interoperative setting with a low-cost camera sensor.
The present disclosure provides methods and systems for preparing a metal nanostructure. The nanostructure can have a unique two-dimensional (2D) anisotropic morphology and a thickness of below 10 nm. In various embodiments, colloidally synthesized gold nanoparticles can be used for the present methods and systems. Advantageously, the present disclosure provides an effective approach to prepare nanofilms useful for many applications.
B30B 1/00 - Presses, utilisant un élément pilonnant, caractérisées par le mode d'entraînement du pilon, la pression étant transmise au pilon ou à la platine de presse directement ou uniquement par l'intermédiaire d'organes travaillant en simple poussée ou traction
17.
VACCINE CONTAINING RBD2 OF CDTB COMPONENT FROM BINARY TOXIN CDT OF CLOSTRIDIOIDES DIFFICILE
A method and a system for identifying authenticity of an electronic component is disclosed. The method may include obtaining chip data of an electronic component; extracting feature information of the chip data for reducing noise of the chip data; providing the feature information of the chip data to a trained deep learning model; and providing a user with an authenticity indication for the electronic component based on an output of the deep learning model. Other aspects, embodiments, and features are also claimed and described.
The present disclosure provides for a method of treating fetal growth restriction in a fetus comprising obtaining a blood sample from a pregnant subject; isolating cell-free fetal DNA from the blood sample; testing the cell-free fetal DNA for a first DNA methylation level of 0.5800 or less in a group of genes, wherein the group of genes comprises the genes of any one of Tables 19-21, wherein the first DNA methylation level is calculated via an average of all differentially methylated islands of cytosine and guanine dinucleotides separated by only one phosphate in the 5' to 3' direction (5'-C-phosphate-G-3') (CpGIs) in differentially methylated regions (DMRs); and when the first DNA methylation level is 0.5800 or less, selecting a treatment from the following: monitoring the fetus during pregnancy of the pregnant subject, tracking movements of the fetus, admitting the pregnant subject to a hospital prior to going into labor, inducing early delivery of the fetus, performing an emergency Cesarean section on the pregnant subject, administering corticosteroids to the pregnant subject, or administering corticosteroids to the fetus upon birth. Other related methods are disclosed herein.
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
20.
SURFACE MODIFIED CARBON QUANTUM DOTS AND METHODS OF MAKING AND USE THEREOF
Disclosed herein are surface modified carbon quantum dots and methods of making and use thereof. For example, described herein are surface modified carbon quantum dots comprising a carbon quantum dot (e.g., a quantum dot comprising carbon) having an exterior surface, and a plurality of ligands conjugated to the exterior surface of the carbon quantum dot. In some examples, the plurality of ligands comprise a fluorescent dye, a polyphenolic compound, or a combination thereof.
A method and a system for identifying authenticity of an electronic component is disclosed. The method may include obtaining chip data of an electronic component: extracting feature information of the chip data for reducing noise of the chip data: providing the feature information of the chip data to a trained deep learning model; and providing a user with an authenticity indication for the electronic component based on an output of the deep learning model. Other aspects, embodiments, and features are also claimed and described.
Embodiments of the present disclosure automate the identification of gonotrophic stages in mosquitoes. An example computer-implemented method can include: receiving an image data set; processing at least a portion of the image data set using an image segmentation operation to determine a current gonotrophic phase for each of at least a portion of the plurality of mosquitoes; determining, using a trained machine learning model and based at least in part on the determined current gonotrophic phases, a predictive output indicative of an expected population of mosquitoes at the location during a future time period; and outputting an indication of the expected population of mosquitoes.
G06V 40/10 - Corps d’êtres humains ou d’animaux, p. ex. occupants de véhicules automobiles ou piétonsParties du corps, p. ex. mains
G06V 10/26 - Segmentation de formes dans le champ d’imageDécoupage ou fusion d’éléments d’image visant à établir la région de motif, p. ex. techniques de regroupementDétection d’occlusion
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
G06V 10/776 - ValidationÉvaluation des performances
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 20/52 - Activités de surveillance ou de suivi, p. ex. pour la reconnaissance d’objets suspects
23.
SCALABLE NANOMANUFACTURING OF ATOMICALLY-THIN, HIGHLY-ALIGNED, HIGH-ASPECT-RATIO, HOMOCHIRAL NANORIBBONS, NANOWIRES, AND QUANTUM WIRES WITH ANGSTROM-PRECISE MORPHOLOGY
Deformation-induced formation of repeatably spatially-scalable nanowires / quantum wires / nanoribbons / nanogaps in a substantially single monolayer 2D material with the use of purely physical (in a specific case - purely mechanical) approach. The resulting one-dimensional (ID), linear 2D-nanoribbon/nanowire/quantum wire/nanogap structures exhibit highly uniform width, spacing, alignment, chemistry, and angstrom-precise edge chirality.
G01N 3/08 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique par application d'efforts permanents de traction ou de compression
G01N 3/20 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique en appliquant des efforts permanents de flexion
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
B82Y 40/00 - Fabrication ou traitement des nanostructures
24.
Methods for optimizing a transmittance and/or a self-cleaning property of a substrate using a self-cleaning coating
2”)-based solution via a light treatment. The substrate may be treated using a combination including but not limited to wet chemicals, dry-cleaning, and/or mechanical polishing. Additionally, the substrate may then be overlayed with a self-cleaning coating, such that the transmittance and the self-cleaning properties of the substrate may be optimized. Furthermore, the methods for optimizing the transmittance and/or the self-cleaning functionality of the substrate may also enhance self-cleaning, anti-fouling, anti-fogging, anti-icing characteristics of the substrate.
B05D 5/00 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers
B01J 21/06 - Silicium, titane, zirconium ou hafniumLeurs oxydes ou hydroxydes
B01J 31/38 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant en outre des composés métalliques inorganiques non prévus dans les groupes du titane, du zirconium ou du hafnium
B05D 3/00 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliquésTraitement ultérieur des revêtements appliqués, p. ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides
25.
CELL CULTURE DISHES WITH DYNAMICALLY RECONFIGURABLE SURFACE TEXTURES FOR CELL EXPANSION AND HARVESTING
Cell culture substrates that rapidly release cells, including a patterned copolymer including a stimulus-responsive polymer and methods of making and using the same.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
26.
METHODS OF INHIBITING FOXO1 FOR TREATMENT OF LYMPHATIC DISORDERS
Disclosed are methods for treating congenital lymphedema or increasing lymphatic valve growth by administering a FOXO1 inhibitor. Also disclosed are methods for increasing nuclear β-catenin activity in a cell by contacting the cell with a FOXO1 inhibitor.
An electrode device and related methods of use and manufacture are described. The electrode can be configured to be securely mounted to a patient's nerve and so that individual contacts are put in electrical communication with individual nerves in a nerve bundle.
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/375 - Aménagements structurels, p. ex. boîtiers
28.
System and method for the activation of active ion transporters without the consumption of adenosine triphosphate (ATP) molecules for the treatment of muscle fatigue
A system and method to control the Na/K pumps for the treatment or prevention of muscle fatigue by applying a synchronization modulation electric field that is effective in synchronizing the Na/K pumps down to individual steps throughout the pumping cycle, thereby synthesizing one ATP for each pumping cycle. The generated ATP molecule compensates the ATP consumed in extrusion of 3 Na ions and pumping 2 K ions such that the net-consumption of ATP for the Na/K pumps controlled by the system and method of the present invention is significantly reduced, theoretically to zero, thereby providing an effective treatment for muscle fatigue.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
An exemplary integrated circuit design lockout system comprises an integrated circuit and a key obfuscated circuit embedded with the integrated circuit. The key obfuscated circuit is configured to verify that a user provides a valid key for the integrated circuit before the user is allowed to operate the integrated circuit. The exemplary integrated circuit design lockout system further comprises a lockout circuit embedded with the key obfuscated circuit, wherein the lockout circuit is configured to allow for a threshold number of failed attempts for the user to provide the valid key before the lockout circuit prohibits the user from making any further attempts at providing the valid key for the integrated circuit.
G06F 21/72 - Protection de composants spécifiques internes ou périphériques, où la protection d'un composant mène à la protection de tout le calculateur pour assurer la sécurité du calcul ou du traitement de l’information dans les circuits de cryptographie
Approaches to producing modular electronic packages include modular arrangements that operate from DC up to 110 GHz and are presented using additive manufacturing such as 3D printing and laser-machining. A method includes assembling electrical circuits from circuit components positioned on modular substrate sections by identifying respective positions of selected components of the electrical circuits on an original substrate; mapping a cut path across the original substrate, wherein the cut path is determined by the respective positions of the selected components; cutting the original substrate along the cut path, wherein the cut path separates the selected components of the electrical circuits onto substrate pieces defining respective side portions; and mating the respective side portions of the respective substrate pieces with corresponding side portions of other substrate sections to assemble the electrical circuits across substrate junctions.
In some aspects, the techniques described herein relate to a method and apparatus for testing a system including: obtaining a design of a system to be tested by a computing device; generating a plurality of traces based on the design of the system by the computing device; training a model of the system using the generated traces by the computing device; generating a plurality of attack traces for the model of the system by the computing device; attacking the model of the system using the generated plurality of attack traces by the computing device; validating some of the plurality of attack traces by the computing device; for each attack trace that is validated, determining possible system vulnerability based on the validated attack trace by the computing device.
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p. ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
32.
System of and method for predicting and/or casting a vote via brain activity
Described herein relates to a system of and method for predicting and/or casting votes via a brain-computer interface. The voting system may be configured to allow at least one user to input and/or cast a vote using their brain activity. Additionally, the voting system uses a machine learning and/or classifying algorithm for classification of the brain data and prediction of the vote of the user. The voting system is also configured to synchronize brain activity to the at least one user, such that each vote may be correctly tallied to the at least one user, eliminating fraudulent voting via false identification, or the like. The voting system may also allow at least one user having a motor disability to vote without requiring any movement and/or physical assistance, such that the at least one user with a motor disability may maintain voting privacy.
A system and method for real-time detection of anomalies in high-dimensional systems. Various embodiments detect anomalies quickly and accurately to allow adequate time for appropriate countermeasures to be implemented. The sequential and multivariate anomaly detection method scales well to high-dimensional datasets using a nonparametric and semi-supervised approach that trains only on nominal data.
Disclosed herein is a 3D printed heart model with simulated cardiac stroke volumes. It involves an inner membrane conforming to the shape of the inner lining of the ventricle. This results in the creation of a compression pouch with a potential space (compression sac) bordered by the inner surface of the simulated ventricle and the outer surface of the inner membrane. The inner membrane also defines a neo-ventricular chamber that is in contact with blood simulating fluid. A pulsatile flow pump can serve as a hydrodynamic driver for inflow and outflow into and out of the compression sac. This can exert a concentric force that compresses the inner sac and displaces the simulated blood residing in the neo ventricular cavity simulating systole. The fluid can then return back from the compression sac to the pump allowing the neo-ventricle to distend to accommodate returning simulated blood from the atrium simulating diastole.
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
Systems and methods are provided herein for determining areas of low blood flow, low blood perfusion, suboptimal treatment perfusion, and/or likelihood of tumor recurrence. For example patient-specific methods are provided for identifying areas of low perfusion in an anatomy of interest (such as a vascular region). Angiography data corresponding to the anatomy of interest can be used to generate a modified three-dimensional (3D) model of the anatomy of interest, which represents a fluid flow system exhibiting variant flow patterns. The model can take into account patient-specific data to simulate physical characteristics of the fluid flow system. This provides for accurate determination of localized areas of low perfusion, which can be indicative of potential tumor recurrence.
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
The present disclosure describes various aspects of devices and methods that are directed to systems for controlling power systems. A device comprises at least one power source unit having a plurality of physical unit pins, at least one sensor to measure a characteristic of at least one power source unit, and a microcontroller. The microcontroller comprises a memory with at least virtual unit object, at least one virtual sensor object, and a set of software instructions to cause the microcontroller to control the at least power source unit via at least one switch using a three-layer control scheme.
A novel method of treating cancer is presented. API transcriptionally regulates SHIP-1 expression via the suppression of miRNA-155, impacting anti-tumor immune responses in the bone marrow (BM) and TME of mice with PC. The inventors discovered that API reduced miRNA-155 in the PC milieu, which induced SHIP-1 expression. This promoted the restoration of myelopoiesis and increased anti-tumor immune responses in the TME of heterotopic, orthotopic and transgenic SHIP-1 knockout preclinical mouse models of PC. The results suggest that manipulating SHIP-1 through miR-155 can assist in augmenting anti-tumor immune responses and aid in the therapeutic intervention of PC. Further, administration of both API and an miR-155 inhibitor were found to act synergistically to treat pancreatic cancer.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
Methods for type 1 diabetes (T1D) regulation include gene electrotransfer (GET) for the delivery of nucleic acid encoding at least one of insulin and glucokinase are provided herein. Avoiding the need for immunomodulation as required for standard gene therapy approaches, the application of electrical pulses enables plasmid uptake for the production of insulin and glucokinase in target cells. GET plasmid delivery provides long-term T1D treatment by regulating glucose levels.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
39.
VARYING THE COUPLANT OR RATIO OF MIXTURES INSIDE OR OUTSIDE OF AN ENCLOSED OR OPEN NON-DESTRUCTIVE TESTING DEVICE
Disclosed herein is a testing device comprising a housing, a first couplant agent, and a transducer disposed in the housing, wherein the housing has a proximal end and a distal end; and a packaging material having a proximal end and a distal end, wherein the proximal end of the packaging material is coupled to the distal end of the housing to form a first interface. The first couplant includes two or more components, of which the ratio of the components is varied to decrease an acoustic impedance mismatch. The device may further have a second couplant disposed on the distal end of the packaging material, which is in contact with a testing material. A method of use of the testing device is also disclosed.
G01N 29/28 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet Détails pour établir le couplage acoustique
Disclosed herein is a method of preparing macromolecular structures for analysis, including placing a macromolecular sample on a surface acoustic wave (SAW) device including: a piezoelectric surface, a first transducer in contact with the piezoelectric surface, a second transducer in contact with the piezoelectric surface, and a sample region disposed between the first transducer and the second transducer and configured to receive the macromolecular sample, the sample region configured to remain electrically isolated from each of the first transducer and the second transducer; applying disruption electrical energy, having a disruption frequency and a disruption power, to each of the first transducer and the second transducer to transform the macromolecular sample into a disrupted macromolecular sample; and applying nebulization electrical energy, comprising a nebulization frequency and a nebulization power, to each of the first transducer and the second transducer, to transform the disrupted macromolecular sample into a nebulized macromolecular sample.
H01J 49/16 - Sources d'ionsCanons à ions utilisant une ionisation de surface, p. ex. émission thermo-ionique ou photo-électrique
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
41.
METHODS FOR DETECTING AND TREATING PROPRANOLOL SENSITIVE TUMORS
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
42.
SYSTEMS AND METHODS FOR INTERPRETING LANGUAGE USING AI MODELS
Systems and methods for artificial intelligence (AI)-based systems are described herein. In an aspect, the present disclosure relates to a computer implemented method that includes prompting a first trained large language model (LLM) to generate a plurality of arguments; determine a ranking of the plurality of arguments using a second trained LLM; and training a third LLM based on the ranking of the plurality of arguments and the plurality of arguments.
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
44.
SEQUENTIAL PACKETS IMAGE-BASED NETWORK INTRUSION DETECTION SYSTEM
The disclosed technology provides a method for detecting malicious activity in a network communication system. A first packet of a first flow is received from the network communication system. The first packet comprises a first sequence of data values. The first sequence of data values is converted to a first plurality of pixel image attribute values. A first portion of an image is generated based on the first plurality of pixel image attribute values. The image is processed using a trained neural network model to determine a likelihood of malicious activity in the first flow.
H04L 41/16 - Dispositions pour la maintenance, l’administration ou la gestion des réseaux de commutation de données, p. ex. des réseaux de commutation de paquets en utilisant l'apprentissage automatique ou l'intelligence artificielle
45.
SYSTEM AND METHOD FOR INCREASED RESILIENCY OF MOBILE WIRELESS NETWORKS VIA DISTRIBUTED PUBLIC-KEY INFRASTRUCTURE (PKI) ALLIANCES
Systems, devices, and methods are disclosed herein that implement efficient frameworks for Public-Key Infrastructure (PKI) functions. In some implementations of such frameworks, a PKI alliance may comprise multiple, independent certification authorities (CAs), that can coordinate signing operations for digital certificates based on umbrella public keys that a device can use for authentication with any of the CAs. Some embodiments may use multi-party computational thresholding in such signing operations. In other aspects, a device may generate an umbrella public/private key pair, and obtain a digital certificate for the umbrella public key which can be used for efficient network handoffs among CAA members and other secure connections.
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
The present disclosure is directed to compounds of Formula (I), (II), (III), and/or (IV), or pharmaceutically acceptable salts, that modulate stimulator of interferon genes (STING), compositions comprising such compounds, and methods of using same for detection and for treatment of disorders such as cancer and autoimmune disease.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
48.
TRANSIENTLY POROUS CRYOGEL COMPOSITE STRUCTURES FOR FAST CARBON DIOXIDE CAPTURE FROM AIR FOR USEFUL CHEMICAL PRODUCTS
A superporous material comprises: a crosslinked linear polyethyleneimine (PEI) microgel comprising the reaction product of linear polyethyleneimine and a crosslinker; an embedded body; and amine functional groups, wherein the embedded body and amine functional groups are available for CO2 association. There is disclosed a method of removing CO2 from a fluidic waste stream, wherein the method comprises contacting the waste stream with the superporous material, wherein the CO2 from the fluidic waste stream bonds to an amine functional group in the superporous material. There is also disclosed a method of removing CO2 from a fluidic waste stream, wherein the method comprises contacting the waste stream with the catalytic superporous material and a flowing gas, and converting CO2 to at least one of methanol, ethanol, carbonic acid, and methane.
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 31/16 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
The present disclosure provides a class of polymeric material comprising units with crown- ether- and cyclodextrin-based structure and preparation method thereof. Advantageously, the present polymeric material may be useful in lithium ion recovery with desirable reusability and/or metal ion selectivity.
C22B 3/24 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques par adsorption sur des substances solides, p. ex. par extraction avec des résines solides
Pulsed electric field methods and systems for applying a pulsed electric field therapy are provided. A system includes a control unit comprising a controller, an impedance measurement system in communication with the controller, and a pulse generator controlled by the controller. The system also includes a handle coupled to the control unit. The handle includes a radiation source controlled by the controller and a temperature measurement system in communication with the controller. The system further includes an electrode array cartridge removably coupled to the handle. The electrode array cartridge includes an array of independently addressable electrodes in communication with the impedance measurement system and the pulse generator, and a series of holes between the electrodes to enable heat from the radiation source in the handle to reach a target tissue and temperature measurements of the target tissue to be obtained by the temperature measurement system in the handle.
A61B 18/08 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par chauffage à l'aide de sondes chauffées électriquement
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
51.
HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER
The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, in the treatment and prevention, and in particular in the treatment, of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof, as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s) or for alleviating cognitive deficit in an individual affected by a disorder selected from the group consisting of Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
52.
Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
This invention relates to a method and apparatus for creating a three-dimensional structure from a binder-free powder. A corona discharge (plasma) generator forms a controllable electric field, positioning the binder-free powder within the influence of the electric field generated by the corona discharge generator, and activating the corona discharge generator to attract the binder-free powder into a three-dimensional structure. The corona discharge generator includes a grounded bottom substrate and a top substrate elevated above the bottom substrate in a substantially parallel planar orientation. The binder-free powder is placed in the interstitial space between the bottom substrate and the top substrate. An electrode above the top substrate, in electrical communication with the bottom substrate and coupled to a voltage power supply, creates the electrical field. The resulting three-dimensional structure is formed far more rapidly than known additive manufacturing techniques.
B29C 64/268 - Agencements pour irradiation par faisceaux laserAgencements pour irradiation par faisceaux d’électrons [FE]
B29C 64/153 - Procédés de fabrication additive n’utilisant que des matériaux solides utilisant des couches de poudre avec jonction sélective, p. ex. par frittage ou fusion laser sélectif
Disclosed is a method of pretreating a sample including DNA adducts for DNA adductomics, the method including the steps: passing a mobile phase including the sample through a first solid phase extraction (SPE) stationary phase; collecting the mobile phase that passes through the first SPE stationary phase; passing a first eluent through the first SPE stationary phase to elute the DNA adducts; passing the collected mobile phase that passed through the first SPE stationary phase through a second SPE stationary phase; passing a second eluent through the second SPE stationary phase to elute the DNA adducts; combining DNA adducts eluted from the first and second SPE stationary phases; analyzing the DNA adducts by liquid chromatography mass spectrometry (LC-MS); wherein either the first or second SPE stationary phase is a hypercrosslinked, hydroxylated polystyrene-divinylbenzene copolymer and the other SPE stationary phase is a phenyl polymer.
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventeur(s)
Muncey, Aaron
Enderling, Heiko
Pasetto, Stefano
Passaglia, Christopher
Yarinsky, Jacob
Pinto, Carolyna Yamamoto Alves
Blocker, Abby
Abrégé
A ventilator device for co-ventilation of multiple patients may include an air tube splitter having an inlet, a plurality of outlets, and a plurality of branches each extending to a respective outlet, a plurality of valves coupled to the branches, a plurality of actuators coupled to the valves, and a controller in operable communication with the actuators. Each valve may be configured to be adjusted to regulate air flow through a respective branch. Each actuator may be configured to adjust a respective valve. The controller may be configured to receive a set of inspiratory pressure settings or tidal volume settings for the patients and independently control the actuators to adjust the valves based at least in part on the set of inspiratory pressure settings or tidal volume settings. The controller may employ time-multiplexing in controlling the actuators to adjust the valves for ventilating the patients at different times.
For systems subject to unbalanced faults, analytical model building for stability assessment is a challenging task. This application presents a straightforward modeling approach. A generalized dynamic circuit representation is achieved by use of the Laplace transform variables. The voltage and current relationship at the fault location is translated into the relationship of three subsystems. The final circuit model is an interconnected sequence network with impedances in the Laplace domain. This circuit can be directly converted from a steady-state sequence network.
G06F 11/22 - Détection ou localisation du matériel d'ordinateur défectueux en effectuant des tests pendant les opérations d'attente ou pendant les temps morts, p. ex. essais de mise en route
57.
STING MODULATORS, COMPOSITIONS, AND METHODS OF USE
The present disclosure is directed to compounds of Formula (I), or pharmaceutically acceptable salts thereof and compounds of Formula (II), or pharmaceutically acceptable salts thereof, that modulate stimulator of interferon genes (STING), compositions comprising such compounds, and methods of using same for the treatment of disorders such as cancer and autoimmune disease.
C07D 213/74 - Radicaux amino ou imino substitués par des radicaux hydrocarbonés ou par des radicaux hydrocarbonés substitués
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
58.
ACTIVATION OF E6AP/UBE3A-MEDIATED PROTEIN UBIQUITINATION AND DEGRADATION PATHWAYS BY A CYCLIC GAMMA-AA PEPTIDE
Georgia State University Research Foundation, Inc. (USA)
Inventeur(s)
Cai, Jianfeng
Huang, Bo
Yin, Jun
Zhou, Li
Liu, Ruochuan
Abrégé
Novel cyclic γ-AA peptides and methods of use thereof in modulating E3 activity are presented. Each novel compound is comprised of four γ-AA building blocks. It was found that in particular, compound P6 activated E6AP to stimulate self-ubiquitination of E6AP and E6AP-catalyzed substrate ubiquitination as well as enhance the ubiquitination of E6AP substrates in the cell and accelerate their degradation.
A material composition includes a photocatalyst and particles of a semiconductor oxide coated with a plurality of nanoparticles of a non-oxidizing metal alloy. The plurality of nanoparticles of a non-oxidizing metal alloy has an average surface area ranging from about 0.1 µm to about 10 µm, and the plurality of nanoparticles of a non-oxidizing metal alloy includes a blend of nanoparticles having different geometric shapes. The semiconductor oxide has a bandgap between 3.875 eV and 2.75 eV.
B01J 21/06 - Silicium, titane, zirconium ou hafniumLeurs oxydes ou hydroxydes
B01D 53/94 - Épuration chimique ou biologique des gaz résiduaires des gaz d'échappement des moteurs à combustion par des procédés catalytiques
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
60.
MATERIAL AND ARTICLES FORMED FROM REFUSE MATERIALS AND METHODS OF MAKING THE SAME
Disclosed herein is a method comprising: providing a refuse collection comprising a first polymer mixture in an amount of greater than 0 wt % to less than 100 wt %, wherein the first polymer mixture comprises a second polymer mixture, wherein the second polymer mixture is about 20 wt % to about 100 wt % of the first polymer mixture and comprises at least one of polyethylene (PE), polypropylene (PP), polystyrene (PS), polyethylene terephthalate (PET), polyvinyl chloride (PVC), or any combination thereof; granulating the first polymer mixture to form a third polymer mixture; and extruding the third polymer mixture to form an article having a strength of about 200 psi to about 5,000 psi.
B29B 7/42 - MélangeMalaxage continu, avec dispositifs mécaniques de mélange ou de malaxage avec dispositifs de mélange ou de malaxage mobiles rotatifs avec un seul arbre à vis ou à vis sans fin
In some aspects, the techniques described herein relate to a method including: receiving a data stream from one or more power plants at the same location by a computing device; based on the received data stream, determining a grid impedance of the one or more power plants with respect to a grid by the computing device; based on the received data stream, determining power plant control parameters and communication delay for each of the one or more power plants; and modeling the integrated system consisting of the one or more power plants and the grid based on the determined grid impedance and the power plant control parameters by the computing device.
H02J 3/38 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs
H02J 13/00 - Circuits pour pourvoir à l'indication à distance des conditions d'un réseau, p. ex. un enregistrement instantané des conditions d'ouverture ou de fermeture de chaque sectionneur du réseauCircuits pour pourvoir à la commande à distance des moyens de commutation dans un réseau de distribution d'énergie, p. ex. mise en ou hors circuit de consommateurs de courant par l'utilisation de signaux d'impulsion codés transmis par le réseau
62.
DUAL FUNCTION HYBRID NANOPARTICLES AND METHODS OF USING THE SAME TO TREAT DISEASES AND DISORDERS
Disclosed herein are siRNAs, hybrid nanoparticles comprising the siRNAs, pharmaceutical compositions comprising the same, and methods of making and using the same to treat neurological diseases and disorders.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
63.
DYNAMIC MEMORY MANAGEMENT ON GRAPHICS PROCESSING UNITS
An example system comprises a memory, one or more processors coupled with the memory and configured to execute a plurality of threads, and a memory controller. The memory controller receives a request to allocate memory space for a first thread of the plurality of threads. The memory controller selects a first memory page from a plurality of memory pages in the memory. The memory controller determines whether the first memory page is currently allocated. The memory controller allocates the first memory page for the first thread based on a determination that the first memory page is not currently allocated. The memory controller selects a different memory page from the plurality of memory pages for the request based on a determination that the first memory page is currently allocated.
e.ge.ge.g., type I diabetes, type II diabetes), and obesity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
65.
MULTIFRACTAL ANALYSIS OF SURFACE POTENTIAL FOR CANCER DIAGNOSIS
Methodology of determination of whether a target biological cell is cancerous based on measurement of the surface potential of such cell and comparing it with the measurement of the surface potential of a normal cell using multifractal analysis to characterize the time-averaged spatial fluctuations of the surface potential. Determinative increase of multifractality of the surface potential is indicative of the cancerous nature of the target cell. Multifractality in surface potential can also be used as a novel biomarker for novel drug delivery methods based on bioelectric activation.
A system and method utilizing a novel waveform structure based on unique word (UW)-orthogonal frequency division multiplexing (OFDM) is proposed for the applications of joint radar-sensing and communication (JRC). A predetermined chirp sequence is used as the UW in the waveform. The predetermined chirp sequence is used to perform radar functionality, which also increases power efficiency of linear power amplifier that is critical for radar applications.
A method and system disable executable script in requested displayable content. Responsive to requesting displayable content, a non-executable code sequence and a mis-matched font file that maps a plurality of characters of the requested displayable content to the non-executable code sequence is received. The non-executable code sequence is displayed as a text string in accordance with the received mis-matched font file.
An exemplary system and method are disclosed that employ dq admittance extraction or identification based on Gaussian time-domain pulse excitation. A narrow time-domain pulse has a wide frequency spectrum. Two or more narrow time-domain pulses can be injected, as simulated transients, into a utility infrastructure with one or multiple inverter-based resources to perturb the system with a wide frequency spectrum that overs the frequencies of interest.
A system is developed employing deep neural networks from natural language processing for the automatic generation of test questions (items) for educational assessments. The system includes: at least one computing device; and a non-transitory computer-readable medium with computer-executable instructions stored thereon that when executed by the at least one computing device cause the at least one computing device to: receive a plurality of items; place the items of the plurality of items in an item bank; for each item in the item bank, generate a score for at least one psychometric property of the item; sort each item in the item bank based on the generated scores; generate a prompt for an item generator based on the sorted items; receive a generated set of items from the item generator based on the generated prompt; and add at least some of the generated set of items to the item bank.
Methodology of Surface-Enhanced Raman Spectroscopy with the use of a rough Al substrate to image the biochemical composition of only the plasma membrane (and substantially without the contribution, to the SERS, of the contents of the inside of an imaged cell, thereby differentiating one from another) of intact cancerous cells and intact normal non-cancerous cells. The judiciously generated roughness of the Al substrate resulted in formation of many hot spots that provided a uniform membrane signal. The peak ratios of the resulting Raman signals specific to the cell-membrane only exhibited heterogeneous properties of the membrane with different lipid and protein concentrations at different spatial locations and are identified and can be used as novel cancer biomarkers. The proposed methodology may be extended to studying the nanoscale composition of lipid rafts and protein aggregates in intact biological cells.
A fluid flow conditioning apparatus having a plurality of flexible microstructures that reduce flow losses within a conduit. The plurality of microstructures is affixed to an insertion plate-type flow conditioner. One or more ends of the microstructures are secured to internal walls of the flow conditioner. The microstructures are configured to move and flex in response to static and dynamic pressure exerted onto the microstructures by the fluid flow. The microstructures may be made of a hyperelastic material configured to undergo an elastic deformation due to the dynamic pressure of the fluid flow.
Methods and systems for obstructive sleep apnea diagnosis and prediction are disclosed. The methods and systems include: obtaining a white noise contaminated sensor signal for a patient; extracting a feature based on the white noise contaminated sensor signal; determining a matrix based on the feature; determining an intermittent forcing signal based on the matrix; determining an overcomplete representation of the intermittent forcing signal; and generating an obstructive sleep apnea indication based on the overcomplete representation and a threshold. Other aspects, embodiments, and features are also claimed and described.
The present disclosure provides for a method of decreasing heparan sulfate expression in a subject in need thereof, the method comprising administering an inhibitor of EXT1 gene expression, wherein the inhibitor comprises a therapeutically effective amount of vitamin D. Further provided herein, is a method of treating cancer in a subject in need thereof, the method comprising administering an inhibitor of EXT1 gene expression, wherein the inhibitor comprises a therapeutically effective amount of vitamin D.
Radio frequency (RF) fingerprinting is a hardware-based authentication technique based on distinct distortions in the received signal due to the unique hardware differences of the transmitting device. Existing RF fingerprinting methods only utilize the naturally occurring hardware imperfections during fabrication, hence their authentication accuracy is limited in practical settings even when state-of-the-art deep learning classifiers are used. In this work, we propose a Chaotic Antenna Array (CAA) system for significantly enhanced RF fingerprints and a deep learning-based authentication method for CAA. We provide a mathematical model for CAA, explain how it can be cost effectively manufactured by utilizing mask-free laser-enhanced direct print additive manufacturing (LE-DPAM), and comprehensively analyze the authentication performance of several deep learning classifiers for CAA.
G06K 19/073 - Dispositions particulières pour les circuits, p. ex. pour protéger le code d'identification dans la mémoire
G06K 7/10 - Méthodes ou dispositions pour la lecture de supports d'enregistrement par radiation électromagnétique, p. ex. lecture optiqueMéthodes ou dispositions pour la lecture de supports d'enregistrement par radiation corpusculaire
75.
SYSTEM AND METHOD FOR SECURE AGGREGATION FOR PRIVACY-PRESERVING FEDERATED LEARNING
Described herein are systems and methods for securely aggregating federated learning updates for a machine learning model. The method includes executing a set-up routine and iteratively executing an aggregation routine and sending the updated machine learning model to each user. The system includes a distributed computing network, the distributed computing network including a plurality of users, a plurality of assisting nodes, and a central server, which aggregates users local model updates.
G05B 19/418 - Commande totale d'usine, c.-à-d. commande centralisée de plusieurs machines, p. ex. commande numérique directe ou distribuée [DNC], systèmes d'ateliers flexibles [FMS], systèmes de fabrication intégrés [IMS], productique [CIM]
G06N 3/006 - Vie artificielle, c.-à-d. agencements informatiques simulant la vie fondés sur des formes de vie individuelles ou collectives simulées et virtuelles, p. ex. simulations sociales ou optimisation par essaims particulaires [PSO]
76.
PREDICTIVE PATH COORDINATION IN MULTI-ROBOT SYSTEMS
A system and methods for operating a multi-robot system (MRS) are disclosed. An example method can include receiving at least one transportation task; determining an optimal path for executing the at least one transportation task based at least in part on: (i) one or more transportation task parameters, (ii) a shared global critic function accessible to the first robot and the at least one additional robot, and (iii) a local critic function unique to the first robot; and executing the at least one transportation task in accordance with the determined optimal path.
G05D 1/644 - Optimisation des paramètres de parcours, p. ex. consommation d’énergie, réduction du temps de parcours ou de la distance
G05D 1/667 - Livraison ou récupération de charges utiles
G05D 101/15 - Détails des architectures logicielles ou matérielles utilisées pour la commande de la position utilisant des techniques d’intelligence artificielle [IA] utilisant l’apprentissage automatique, p. ex. les réseaux neuronaux
G05D 107/70 - Sites industriels, p. ex. entrepôts ou usines
An example method includes receiving a text string; generating, by a first machine learning model, a feature values for the text string, where the feature values correspond to attributes of the text string; inputting the text string and the plurality of feature values into a second machine learning model; and generating, by the second machine learning model, a formal representation of the text string.
The present disclosure describes methods of detecting the presence and/or the level of Alu RNA in a subject sample, using a novel competitive reverse-transcription PCR and in situ hybridization methods and reagents.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
Disclosed herein is a concrete composition comprising: a) a cement in an amount of about 25 wt % to about 70 wt % based on a total mass of dry material; b) a rubber in an amount of about 15 wt % to about 35 wt % on a total mass of dry material; and c) fine aggregates in an amount of about 10 wt % to about 35 wt % on a total mass of dry material; wherein the concrete composition is substantially free of coarse aggregates. Additionally, articles comprising the disclosed herein composition are also disclosed. Also disclosed are methods of making the compositions and the articles.
C04B 40/00 - Procédés, en général, pour influencer ou modifier les propriétés des compositions pour mortiers, béton ou pierre artificielle, p. ex. leur aptitude à prendre ou à durcir
80.
Systems and methods for finger-to-thumb crease testing
In one embodiment, a system for finger-to-thumb crease testing includes a patient interface configured to attach to a thumb of a patient, the patient interface including a touch sensor configured to sense contact between a finger of the patient and the touch sensor, the touch sensor being positioned on the patient interface in a location at which it overlies a distalmost thumb crease of the thumb when the patient interface is attached, and a control module in electrical communication with the patient interface, the control module being configured to count a number of times the patient successfully taps the touch sensor with the finger.
Disclosed are various embodiments of an apparatus for practicing a reduction procedure for treating radial head subluxation. In one example, the apparatus can include a model arm can be pivotally mounted to and supported by a stand. The model arm includes an upper member that emulates an upper arm of a human, a lower member that emulates a lower arm of a human being, and a joint that pivotally connects the upper member and the lower member. A feedback mechanism can be provided within the joint of the model arm. The feedback mechanism can be configured to provide initial resistance to downward pivoting to the lower member relative to the upper member, to provide an audible and tactile pop when the procedure is successfully performed that emulates the audible and tactile pop that occurs when a human radial head pops back into place during an actual reduction procedure.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventeur(s)
Bickford, Paula
Patel, Niketa
Abrégé
The invention relates to compositions comprising exosomes isolated from human adipose-derived stem cells and their use in a method of treating or preventing Parkinson's disease in a subject.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A probiotic fermented product is disclosed comprising at least four live strains of bacteria, wherein said bacteria are: Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei and Bifidobacterium longum that produce 3-hydroxybutyrate in the probiotic fermented product. Also disclosed herein is a method of treating dysbiosis in a subject with the probiotic fermented product, wherein the dysbiosis can be aging-associated.
Described herein are methods of treating uterine leiomyoma by administering to a patient in need thereof a composition that increases adenosine levels.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
Disclosed are agents, compositions, and methods for use for preventing, inhibiting, or treating inflammation in a subject. The methods include using such agents, compositions for preventing, inhibiting, or treating conditions or diseases associated with inflammation.
The present disclosure describes methods of inducing type III IFN stimulated genes in fetal trophoblast cells to decrease or inhibit vertical transmission of viral infection to the fetus. The method comprises induction of short interspersed nuclear elements in a microRNA cluster.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
90.
COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF ALZHEIMER'S DISEASE
Methods and compositions for treating and/or preventing Alzheimer's disease (AD), and/or for reducing one or more amyloid beta peptides and/or phosphorylated tau (p-tau) in the brain of a subject. The methods can include administering a composition comprising melatonin and cannabidiol (CBD).
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
91.
WITHAFERIN A AND IMMUNE CHECKPOINT BLOCKER COMBINATION THERAPIES
The present disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of withaferin A and an immune checkpoint blocker. Further, the cancer to be treated may be resistant, have developed resistance, or may be susceptible to resistance to treatment with the immune checkpoint blocker alone or in combination with another therapeutic agent other than withaferin A.
A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
Methods are disclosed for auditory dysfunction by administration of a therapeutic agent and stem cells. The therapeutic agent is chosen from disclosed agents that target the CCL20-CCR6 axis. Further disclosed are treatment protocols of said therapeutic agent and stem cells. The method of treatment is disclosed to be treatment following a traumatic brain injury.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Methods and systems for improving communication involving a personal with aphasia are disclosed. The methods and systems include: obtaining an audio input indicative of speech of the person with aphasia; providing the audio input to a personalized aphasia translation assistant, wherein the personalized aphasia translation assistant was trained to recognize and translate speech of the person with aphasia using a general dataset of aphasia-speech; determining a plurality of words from the audio input using an aphasia-specific recognition model; inputting the plurality of words into an aphasia generative model, the aphasia generative model comprising a natural language processing machine learning model trained using a general dataset of aphasia sentences and a corresponding dataset of translated sentences; generating one or more formulated and contextual sentences using the personalized aphasia generative assistant; and outputting the one or more formulated and contextual sentences. A further method provides the training of a personalized aphasia communication assistant, in particular the adaptation of a pre-trained speech recognition model and of a pre-trained generative speech model based on predicted text and a user confirmation feedback of the accuracy of the predicted text.
H. Lee Moffitt Cancer Center and Research Institute, Inc. (USA)
University of South Florida (USA)
Inventeur(s)
Vrionis, Frank D.
Aghayev, Kamran
Gonzalez Blohm, Sabrina A.
Doulgeris, James J.
Abrégé
A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed. The screws include a threaded tip connected to a main shaft and a threaded outer sleeve that rotates relative to the outer shaft until locked down. Independent rotation of the threaded outer sleeve relative to the threaded distal tip allows compression or distraction to modify the gap between the vertebral bodies. The screws are passed from the inferior to superior vertebra or superior to inferior, for example, through a trans-pedicular route to avoid neurological compromise. At the same time, the path of screw insertion is oriented to reach superior or inferior vertebra. An intervertebral cage of the system is configured for lateral expansion from a nearly straight configuration to form a large footprint in the disc space. The screws and cage may be combined for improved fixation with minimal invasiveness.
A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant
CCR2 is involved in the regulation of normal cardiovascular function and during the cardiovascular stress response to hemorrhagic shock and fluid resuscitation. Disclosed herein are methods of using CCR2 inhibitors to reduce fluid requirements and to prevent death from hemodynamic decompensation during resuscitation.
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
98.
System and method for reducing a threat footprint of an area-of-interest
A method for reducing a threat footprint for an area-of-interest by, determining a base risk score for an area-of-interest, deriving a graphical representation of the area-of-interest and one or more defense strategies for the area-of-interest, training an adversarial reinforcement learning agent to identify one or more successful attack paths on the graphical representation of the area-of-interest that are effective in bypassing the one or more defense strategies for the area-of-interest, determining an active risk score based upon the one or more successful attack paths identified by the adversarial reinforcement learning agent and determining one or more mitigation actions that will reduce the active risk score for the area-of-interest based upon the base risk score and one or more predetermined resource constraint.
G08B 21/02 - Alarmes pour assurer la sécurité des personnes
G06F 18/21 - Conception ou mise en place de systèmes ou de techniquesExtraction de caractéristiques dans l'espace des caractéristiquesSéparation aveugle de sources
G06N 3/04 - Architecture, p. ex. topologie d'interconnexion
G06Q 90/00 - Systèmes ou méthodes spécialement adaptés à des fins administratives, commerciales, financières, de gestion ou de surveillance, n'impliquant pas de traitement significatif de données
99.
FRUSTRATED LEWIS PAIR-IMPREGNATED POROUS MATERIALS AND USES THEREOF
Described herein are compositions composed of frustrated Lewis pairs impregnated in porous materials such as, for example, metal-organic frameworks, and their uses thereof. These compositions may allow new applications of frustrated Lewis pairs in catalysis by sequestering and protecting the frustrated Lewis pair within the nanospace of the porous material. Also provided are methods of hydrogenating an organic compound having at least one unsaturated functional group comprising using the compositions described herein.
B01J 31/16 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
C01B 3/00 - HydrogèneMélanges gazeux contenant de l'hydrogèneSéparation de l'hydrogène à partir de mélanges en contenantPurification de l'hydrogène
C07C 67/303 - Préparation d'esters d'acides carboxyliques par modification de la partie acide de l'ester sans introduction d'un groupe ester par hydrogénation de liaisons non saturées carbone-carbone
C07C 209/52 - Préparation de composés contenant des groupes amino liés à un squelette carboné par réduction d'acides carboxyliques ou de leurs esters en présence d'ammoniac ou d'amines ou par réduction de nitriles, d'amides d'acides carboxyliques, d'imines ou d'imino-éthers par réduction d'imines ou d'imino-éthers
C07C 213/02 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions impliquant la formation de groupes amino à partir de composés contenant des groupes hydroxy ou des groupes hydroxy éthérifiés ou estérifiés
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 39/08 - Clostridium, p. ex. Clostridium tetani
A61K 39/40 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire bactériens
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
